Image

Eating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss

Eating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

This project aims to offer a quantitative and qualitative nutritional approach, along with educational nutritional guidelines for participants with Non-Communicable Chronic Diseases. The main goals are: 1- Regularization of eating habits and windows; 2- Modulation of biochemical, anthropometric, and cardiovascular parameters; 3- Increase in knowledge about healthy eating. In this way, participants will undergo a complete nutritional assessment, comprising anthropometry, biochemistry, clinical, and dietary evaluations.

Description

The study will be conducted at the Endocrinology and Hypertension Clinic of the São José do Rio Preto Medical School from 2025 to 2027, aiming to collect data for a thorough analysis of the participants. The study participants will be randomly assigned to 2 groups (intervention 1 and intervention 2). Participants in the first group will follow a daytime eating window (7 am - 7 pm). Participants in the second group will follow a nighttime eating window (12 pm - 12 am). Nutritional consultations will be individual and will occur once every 3 months until the conclusion of the study, according to the clinic's scheduling availability. The average duration of each session will be approximately 1 hour per participant. All participants will be reminded of their appointments via phone/WhatsApp.

Eligibility

Inclusion Criteria:

  • Age: Adults >18 years < 80 years; Diagnosis of obesity, diabetes, and hypertension; Gender: Male and female; Availability to attend quarterly meetings over a period of 18 months; Sedentary.

Exclusion Criteria:

  • Difficulties in responding to the requested instruments; Impediments to regular attendance in data collection; No diagnosis of Obesity, Diabetes, and Hypertension; Use of insulin therapy, Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors, and Glucagon-Like Peptide-1 (GLP-1) analogs; Chronic Kidney Disease patients; Normal weight or undernourished individuals; Physical exercise practitioners (>150 minutes of exercise/week).

Study details
    Type 2 Diabetes Mellitus (T2DM)
    Hypertension
    Obesity and Type 2 Diabetes
    Cardiovascular Diseases

NCT06735859

Federal University of São Paulo

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.